Bronchodilators and exercise in COPD: Effects, evaluation and strategy of use;Bronchodilatateurs et exercice dans la BPCO: Effets, évaluation et stratégie d'utilisation

Revue de Pneumologie Clinique

Volumn 58, Issue 4 II, 2002, Pages

  Perez, T ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BRONCHODILATING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; OXITROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

BICYCLE ERGOMETRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DYSPNEA; EXERCISE; HUMAN; NEBULIZATION; REVIEW; TREATMENT INDICATION;

BRONCHODILATOR AGENTS; CLINICAL TRIALS; DRUG MONITORING; EVALUATION STUDIES; EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 0036755687     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Ikeda A, Nishimura K, Koyama H Tsukino M, Mishima M, Izumi T. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996;51:48-53.
2. Dyer CAE, Singh SJ, Stockley RA, Sinclair AJ, Hill SL. The incremental shuttle walking test in elderly people with chronic airflow limitation. Thorax 2002;57:34-8.
3. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: The six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-82.
4. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med 2000;161:1897-901.
5. Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilatator reversibility in chronic pulmonary disease. Thorax 2001;56:713-20.
6. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
7. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395-9.
8. Bellman MJ, Botnick WC, Shin JW. Inhaled bronchodilatators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967-75.
9. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996;51:689-93.
10. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease. Eur Respir J 1997;10:815-21.
11. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
12. Liesker JJW, Wijkskra PJ, Ten Hacken NHT, Koeter GH, Postma DS, Kerstjens HAM. A systematic review of the effects of bronchodilatators on exercise capacity in patients with COPD. Chest 2002;121:597-608.
13. Leitch AG, Hopkin JM, Ellis DA, Merchant S, McHardy GJ. The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 1978;33:711-3.
14. Corris PA, Neville E, Nariman S, Gibson GJ. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax 1983;38:292-6.
15. Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airway obstruction. Am Rev Respir Dis 1988;138:624-9.
16. Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD? Chest 1995;108:730-5.
17. Patakas D, Andreadis D, Mavrofridis E, Argyropoulou P. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med 1998;92:1116-21.
18. Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998;53:269-73.
19. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. on behalf of the GOLD Scientific Committee. NHLBI/WHO GOLD workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.